Small molecules targeting p53 to improve antitumor therapy

被引：12

作者：

Beretta, G. L. ^{[1
]}

Gatti, L. ^{[1
]}

Benedetti, V. ^{[1
]}

Perego, P. ^{[1
]}

Zunino, F. ^{[1
]}

机构：

[1] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Labs, I-20133 Milan, Italy

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2008年 / 8卷 / 09期

关键词：

p53; nutlins; pifithrins; histone deacetylase inhibitors; ubiquitin ligase inhibitors; apoptosis; cancer cells; drug combination;

D O I：

10.2174/138955708785132774

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of combination strategies with conventional antitumor agents.

引用

页码：856 / 868

页数：13

共 100 条

[1] Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene [J].

Alvarez-Salas, LM ;

Arpawong, TE ;

DiPaolo, JA .

ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1999, 9 (05) :441-450

[2] Inhibitors of apoptosis in lymphocytes:: Synthesis and biological evaluation of compounds related to pifithrin-α [J].

Barchéchath, SD ;

Tawatao, RI ;

Corr, M ;

Carson, DA ;

Cottam, HB .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (20) :6409-6422

[3] Pifithrin-α, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro [J].

Bassi, L ;

Carloni, M ;

Fonti, E ;

de la Peña, NP ;

Meschini, R ;

Palitti, F .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2002, 499 (02) :163-176

[4] Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma [J].

Becker, K. ;

Marchenko, N. D. ;

Maurice, M. ;

Moll, U. M. .

CELL DEATH AND DIFFERENTIATION, 2007, 14 (07) :1350-1360

[5] Anticancer activities of histone deacetylase inhibitors [J].

Bolden, Jessica E. ;

Peart, Melissa J. ;

Johnstone, Ricky W. .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784

[6] Requirement for p53 and p21 to sustain G2 arrest after DNA damage [J].

Bunz, F ;

Dutriaux, A ;

Lengauer, C ;

Waldman, T ;

Zhou, S ;

Brown, JP ;

Sedivy, JM ;

Kinzler, KW ;

Vogelstein, B .

SCIENCE, 1998, 282 (5393) :1497-1501

[7] Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277 [J].

Buzek, J ;

Latonen, L ;

Kurki, S ;

Peltonen, K ;

Laiho, M .

NUCLEIC ACIDS RESEARCH, 2002, 30 (11) :2340-2348

[8] Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs [J].

Bykov, VJN ;

Issaeva, N ;

Zache, N ;

Shilov, A ;

Hultcrantz, M ;

Bergman, J ;

Selivanova, G ;

Wiman, KG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (34) :30384-30391

[9] PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis [J].

Bykov, VJN ;

Zache, N ;

Stridh, H ;

Westman, J ;

Bergman, J ;

Selivanova, G ;

Wiman, KG .

ONCOGENE, 2005, 24 (21) :3484-3491

[10] Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database [J].

Bykov, VJN ;

Issaeva, N ;

Selivanova, G ;

Wiman, KG .

CARCINOGENESIS, 2002, 23 (12) :2011-2018

← 1 2 3 4 5 6 7 8 9 10 →